Digest Network Come funziona
Network
/
Società
Da
Non verificato

Daiichi Sankyo

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

87 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
20/02/2026
Mercato del lavoro
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/02/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
04/02/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
03/02/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
22/01/2026
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
19/01/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
13/01/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Industria
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
07/01/2026
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0
22/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Fonte
Daiichi Sankyo
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0